On 3 September 2026, AKESO (09926.HK) announced that the OS interim analysis of the HARMONi-2 study of ivonescimab (PD-1/VEGF) as first-line treatment for PD-L1-positive NSCLC met the key secondary OS endpoint with statistical significance and clinical benefit; the study had previously met its primary PFS endpoint (median PFS 11.14 vs 5.82 months, HR=0.51).
On 3 September 2026, CHINAGOLDINTL (02099.HK) announced its inclusion in the Hang Seng Momentum Index and the Hang Seng HK Stock Connect SOE Quality Index, with the change to take effect after the market close on 4 September and from 7 September; the Company stated it will continue to advance key projects including the Jiama Mine expansion and underground mining construction at the Changshanhao Gold Mine.
On 3 September 2026, CUTIA-B (02487.HK) announced that the BLA for CU-20101 (botulinum toxin type A for injection) has been accepted by the NMPA for the indication of improving moderate to severe glabellar lines; the product's manufacturing process will not use animal-derived materials or human serum albumin, aiming to eliminate the risks of TSE infection and allergic reactions.
On 2 September 2026, LEADER EDU (01449.HK) announced that its controlling shareholder Shuren Education entered into a sale and purchase agreement with Scienjoy Innovation Labs Inc. to sell 239,234,000 shares (approximately 29.9%) for approximately HKD 102.69 million; upon completion, Shuren together with Junhua Education will still hold 32.18% and remain the controlling shareholders, and the sale is subject to conditions precedent and may or may not proceed.
On 2 September 2026, Hatcher Group Limited (HATCHER GROUP, 08365.HK) published a further voluntary announcement stating that Qianyi Intelligent Technology Co., Ltd. had bought back 36% of the company's interest in Hong Kong KuaJingTong Aviation Technology Co., Ltd. for HKD 1, reducing the group's stake from 51% to 15% upon completion; Hong Kong KuaJingTong has signed a strategic investment LOI with Shenzhen Pengcheng Linghang Low-altitude Industry Co., Ltd. to pursue a low-altitude economy cross-border logistics project, under which Pengcheng Linghang plans to transfer 10% of its equity, commit to purchasing 2,000 commercial drones and lead the introduction of no less than RMB 2 billion in funding. The LOI is not legally binding and the contemplated transactions may not proceed.
On 2 September 2026, China Health Group Inc. (C HEALTH GP, 08225.HK) announced, on a voluntary basis, an update on its receivables recovery: receivables with a carrying amount of RMB 128 million as of 31 December 2024 have been fully provided for; after its arbitration claims against a related party were dismissed in full, the company has applied to set aside the arbitration award and is following up on the court's review; newly collected amounts from customers with a positive repayment attitude totaled RMB 2.088 million since 3 June 2026; and the company has established a receivables management committee to strengthen collection and internal controls, with the final recovery outcome subject to uncertainty.
On 2 September 2026, Victory Giant Technology (HuiZhou) Co., Ltd. (VGT, 02476.HK) published an overseas regulatory announcement in which its A-share unit (300476) disclosed the progress of guarantees between its third-level wholly-owned subsidiaries: Hunan MFS Technology (PCB) Co., Ltd. and Hunan MFS Technology (Hunan) Co., Ltd. signed maximum guarantee agreements with China CITIC Bank Changsha Branch, providing mutual joint and several liability guarantees of RMB 30 million in aggregate; the amounts fall within the company's 2026 estimated guarantee quota of no more than RMB 2,634.45 million and require no further approval. The aggregate outstanding guarantee balance stood at RMB 2,244.3084 million as of the disclosure date, equivalent to 13.51% of audited net assets at end-2025, with no guarantees to entities outside the consolidation scope and no overdue guarantees.
On 2 September 2026, Keymed Biosciences Inc. (KEYMED BIO-B, 02162.HK) announced an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the registration and commercialization of its in-house developed IL-4Rα monoclonal antibody Stapokibart injection (Kangyueda) in 18 countries and regions — 11 in Southeast Asia, 5 in Central Asia, plus Hong Kong and Macao; Keymed will receive an upfront payment, milestone payments and high-double-digit royalties based on net sales, and will continue to handle manufacturing and supply.
On 2 September 2026, Viva Goods Company Limited (VIVA GOODS, 00933.HK) announced that its wholly-owned subsidiary had acquired a further 17,253,500 shares of Li Ning Company Limited (LI NING, 02331.HK) on the open market through the Stock Exchange, representing approximately 0.67% of Li Ning's issued share capital, for a total consideration of approximately HKD 228,207,000 at an average price of approximately HKD 13.23 per share; upon completion, Viva Goods' stake in Li Ning rose from approximately 16.91% to 17.58%, with Li Ning continuing to be accounted for as an associate.
On 2 September 2026, Ocumension Therapeutics (OCUMENSION-B, 01477.HK) announced that its Phase III clinical trial of OT-211 (TRYPTYR, acoltremon ophthalmic solution 0.003%) in China has completed enrollment of an aggregate of 398 patients; the drug is the first TRPM8 agonist approved by the US FDA for the treatment of dry eye disease, and the company secured an exclusive license for the Chinese mainland through a strategic collaboration with Alcon in October 2024.
On 2 September 2026, Global Bio-chem Technology Group Company Limited (GLOBAL BIO-CHEM, 00809.HK) announced that the completion and ignition ceremony of its boiler renovation project was held at its Dehui production base in Jilin Province on 31 August 2026, with the renovated boilers formally put into operation; civil works for the coenzyme Q10 project commenced on the same day, under which its indirect wholly-owned subsidiary Dacheng Dahe produces CoQ10 mycelium for Shenzhou Bio-tech Co., Ltd., marking the Group's entry into synthetic biology and its expansion into medical applications.
On 2 September 2026, Estun Automation Co., Ltd. (ESTUN, 02715.HK) published an overseas regulatory announcement in which its A-share unit (002747) disclosed a plan to repurchase and cancel an aggregate of 322,300 restricted shares held by 21 grantees (10 who had resigned and 11 with a performance grade of B); upon completion, total shares will fall from 968,666,053 to 968,343,753 and registered capital will decrease to RMB 96,834.3753 ten-thousand yuan, with creditors entitled within 45 days of the announcement to require debt repayment or guarantees.
On 2 September 2026, Xinhua News Media Holdings Limited (XH NEWS MEDIA, 00309.HK) announced a placing of up to 5,830,348 new shares at HKD 0.8 per share on a best effort basis, representing a discount of approximately 13.98% to the closing price of HKD 0.93 and approximately 11.19% of the issued share capital, with estimated net proceeds of approximately HKD 4.564 million for general working capital. The placing does not require shareholders' approval and is conditional upon Listing Committee approval, with completion expected on the third business day after all conditions are satisfied.
On 2 September 2026, KEYTOP PARKING (02272.HK) announced that it had filed an application with the CSRC for H-share full circulation, planning to convert all of its 2,857,040 unlisted shares with a par value of RMB 1.0 each into H shares for listing and trading on the Main Board of the Stock Exchange. No further shareholders' meeting is required for the conversion and listing, implementation details are yet to be finalized, and completion remains subject to approvals from relevant domestic and overseas regulators.
On 2 September 2026, Cofoe Medical Technology Co., Ltd. (COFOE MEDICAL, 01187.HK) published an overseas regulatory announcement in which its A-share (301087) results briefing revealed that the second A-share buyback of the year would be fully cancelled while the controlling shareholder increased its H-share holding, and that the company had secured Philips brand licensing for seven health monitoring categories in Greater China, with the first products completing registration. Shareholders totaled approximately 15,000 as of 31 August 2026.
On 2 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637.HK) announced that HX9428 had filed a Phase IIa IND for diabetic macular edema with the CDE of NMPA on 31 August 2026; the Phase I dose-escalation study in neovascular age-related macular degeneration was fully completed, with 13 patients finishing 24 weeks of dosing without additional intravitreal injections and average visual acuity improvement exceeding 5 letters. The drug has received Fast Track Designation from the US FDA.
